Information
131 Gasan digital 1-ro, Geumcheon District, Seoul, South Korea
-
-
-
Overview
- Summary
- QuantaMatrix is an in-vitro diagnostics company established in 2010, spun off from Seoul National University's BiNEL research lab. The company develops 'dRAST', a rapid antimicrobial susceptibility testing system for quick and optimal antibiotic prescription for sepsis patients. Through its next-generation integrated technology 'uRAST', it significantly shortens diagnosis time by combining blood culture, microbial identification, and antimicrobial susceptibility testing. Beyond sepsis, the company is developing and commercializing diagnostic solutions for various diseases, including tuberculosis and Alzheimer's. Recognized for its technological prowess in the global market, it is actively expanding into overseas markets in Europe, the Middle East, and Asia.QuantaMatrix is an in-vitro diagnostics company established in 2010, spun off from Seoul National University's BiNEL research lab. The company develops 'dRAST', a rapid antimicrobial susceptibility testing system for quick and optimal antibiotic prescription for sepsis patients. Through its next-generation integrated technology 'uRAST', it significantly shortens diagnosis time by combining blood culture, microbial identification, and antimicrobial susceptibility testing. Beyond sepsis, the company is developing and commercializing diagnostic solutions for various diseases, including tuberculosis and Alzheimer's. Recognized for its technological prowess in the global market, it is actively expanding into overseas markets in Europe, the Middle East, and Asia.
- Key Products/Technologies
- Its main product lines include the rapid antimicrobial susceptibility testing system 'dRAST' and the next-generation integrated solution 'uRAST'.Its main product lines include the rapid antimicrobial susceptibility testing system 'dRAST' and the next-generation integrated solution 'uRAST'.
- dRAST provides antimicrobial susceptibility test results from positive blood culture samples within 5-7 hours, shortening the time by approximately 48 hours compared to conventional methods.dRAST provides antimicrobial susceptibility test results from positive blood culture samples within 5-7 hours, shortening the time by approximately 48 hours compared to conventional methods.
- This system incorporates AI deep learning technology for rapid interpretation of diverse bacterial growth patterns.This system incorporates AI deep learning technology for rapid interpretation of diverse bacterial growth patterns.
- uRAST is an innovative technology that bypasses the blood culture process, performing microbial identification and antimicrobial susceptibility testing simultaneously, delivering results within an average of 13 hours after blood collection.uRAST is an innovative technology that bypasses the blood culture process, performing microbial identification and antimicrobial susceptibility testing simultaneously, delivering results within an average of 13 hours after blood collection.
- This technology has been published in the prestigious journal Nature, proving its technological excellence.This technology has been published in the prestigious journal Nature, proving its technological excellence.
- The company also possesses a diverse diagnostic product portfolio, including the tuberculosis diagnostic solution 'QDST' and the Alzheimer's early diagnosis auxiliary kit 'QPLEX Alz plus assay'.The company also possesses a diverse diagnostic product portfolio, including the tuberculosis diagnostic solution 'QDST' and the Alzheimer's early diagnosis auxiliary kit 'QPLEX Alz plus assay'.
- A core technology is the QMAP platform, which involves coupling target probes to microdisks engraved with multiple codes.A core technology is the QMAP platform, which involves coupling target probes to microdisks engraved with multiple codes.
- Its development integrates advanced technologies such as semiconductor processes, nanotechnology, optical technology, surface chemical treatment technology, and biochemical technology.Its development integrates advanced technologies such as semiconductor processes, nanotechnology, optical technology, surface chemical treatment technology, and biochemical technology.
- Core Advantages
- Firstly, revolutionary speed in sepsis diagnosis. dRAST shortens diagnosis time by up to 48 hours compared to existing tests, and uRAST provides optimal antimicrobial information within 13 hours without a blood culture step, securing the golden hour for patients.Firstly, revolutionary speed in sepsis diagnosis. dRAST shortens diagnosis time by up to 48 hours compared to existing tests, and uRAST provides optimal antimicrobial information within 13 hours without a blood culture step, securing the golden hour for patients.
- Secondly, high accuracy and integrated diagnostic solutions based on AI deep learning. The uRAST technology, which integrates blood culture, microbial identification, and antimicrobial susceptibility testing into a single process, simplifies the diagnostic procedure and minimizes errors.Secondly, high accuracy and integrated diagnostic solutions based on AI deep learning. The uRAST technology, which integrates blood culture, microbial identification, and antimicrobial susceptibility testing into a single process, simplifies the diagnostic procedure and minimizes errors.
- Thirdly, proven technological capabilities and excellent R&D expertise, including publication in the journal Nature and selection for the US government's CARB-X support. Continuous technological innovation through close collaboration with Seoul National University.Thirdly, proven technological capabilities and excellent R&D expertise, including publication in the journal Nature and selection for the US government's CARB-X support. Continuous technological innovation through close collaboration with Seoul National University.
- Fourthly, extensive global market penetration and competitive advantage across over 30 countries in Europe, the Middle East, and Asia. Demonstrated technological superiority by replacing US competitor products in major medical institutions like Saudi Arabia's Ministry of Defense Hospital.Fourthly, extensive global market penetration and competitive advantage across over 30 countries in Europe, the Middle East, and Asia. Demonstrated technological superiority by replacing US competitor products in major medical institutions like Saudi Arabia's Ministry of Defense Hospital.
- Fifthly, a stable revenue structure through a 'razor-and-blade' business model, where high-margin consumables generate recurring sales after equipment installation.Fifthly, a stable revenue structure through a 'razor-and-blade' business model, where high-margin consumables generate recurring sales after equipment installation.
- Sixthly, a strategic expansion of the product portfolio into various disease diagnostic areas beyond sepsis, such as Alzheimer's and tuberculosis.Sixthly, a strategic expansion of the product portfolio into various disease diagnostic areas beyond sepsis, such as Alzheimer's and tuberculosis.
- Seventhly, creation of socio-economic value through reduced patient mortality, shortened ICU stays, increased hospital operational efficiency, and potential savings of up to 20 million KRW per patient in hospitalization costs.Seventhly, creation of socio-economic value through reduced patient mortality, shortened ICU stays, increased hospital operational efficiency, and potential savings of up to 20 million KRW per patient in hospitalization costs.
- Target Industrie
- Primarily utilized in medical institutions such as hospitals, tertiary hospitals, general hospitals, and clinical laboratories.Primarily utilized in medical institutions such as hospitals, tertiary hospitals, general hospitals, and clinical laboratories.
- Plays a crucial role in the clinical microbiology diagnostics field for infectious diseases like sepsis, bacteremia, and tuberculosis.Plays a crucial role in the clinical microbiology diagnostics field for infectious diseases like sepsis, bacteremia, and tuberculosis.
- Furthermore, potential expansion into the biopharmaceutical sector through the development of aseptic verification technology (NEST) for cell therapy products.Furthermore, potential expansion into the biopharmaceutical sector through the development of aseptic verification technology (NEST) for cell therapy products.
- Potential for technology expansion into diverse industries such as cosmetics, food, and defense.Potential for technology expansion into diverse industries such as cosmetics, food, and defense.
- Major Markets
- Malaysia, Saudi Arabia, Mongolia, RussiaMalaysia, Saudi Arabia, Mongolia, Russia
- France, Poland, Across Europe (over 30 countries with distributor agreements)France, Poland, Across Europe (over 30 countries with distributor agreements)
- United States (FDA clearance pursuit, CARB-X support)United States (FDA clearance pursuit, CARB-X support)
- Certifications/Patents
- Acquisition of numerous domestic and international quality and management system certifications, including venture company certification, medical device manufacturing license, GMP and ISO 9001, 13485 certifications for manufacturing facilities.Acquisition of numerous domestic and international quality and management system certifications, including venture company certification, medical device manufacturing license, GMP and ISO 9001, 13485 certifications for manufacturing facilities.
- Designated as an 'Innovative Medical Device Company' under the 'Innovation Leap Type' by the Ministry of Health and Welfare.Designated as an 'Innovative Medical Device Company' under the 'Innovation Leap Type' by the Ministry of Health and Welfare.
- Obtained CE-IVDR (European In Vitro Diagnostic Medical Device Regulation) certification for its rapid antimicrobial susceptibility testing system dRAST, establishing a foundation for European market entry.Obtained CE-IVDR (European In Vitro Diagnostic Medical Device Regulation) certification for its rapid antimicrobial susceptibility testing system dRAST, establishing a foundation for European market entry.
- Domestically, dRAST achieved New Medical Technology certification and became eligible for national health insurance coverage.Domestically, dRAST achieved New Medical Technology certification and became eligible for national health insurance coverage.
- Holds numerous intellectual property rights, including 18 domestic patent registrations, 2 patent applications, and 17 trademark registrations as of 2021.Holds numerous intellectual property rights, including 18 domestic patent registrations, 2 patent applications, and 17 trademark registrations as of 2021.
- Key patents include culture medium for Gram-positive bacteria, a rapid cell culture testing device for easy observation, and an antimicrobial susceptibility testing device and method (related to dRAST), with multiple dRAST-related patents in the US and Europe.Key patents include culture medium for Gram-positive bacteria, a rapid cell culture testing device for easy observation, and an antimicrobial susceptibility testing device and method (related to dRAST), with multiple dRAST-related patents in the US and Europe.
- Strengthened technological competitiveness through exclusive license agreements and patent transfers for QMAP platform-related core technologies from Seoul National University R&D Foundation.Strengthened technological competitiveness through exclusive license agreements and patent transfers for QMAP platform-related core technologies from Seoul National University R&D Foundation.
- Recognized for its technology and global market pioneering achievements by being selected as a Next-Generation World-Class Product by the Ministry of Trade, Industry and Energy.Recognized for its technology and global market pioneering achievements by being selected as a Next-Generation World-Class Product by the Ministry of Trade, Industry and Energy.
Introduction
Location
131 Gasan digital 1-ro, Geumcheon District, Seoul, South Korea
클릭하여 위치 살펴보기
